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Abstract  29 
Scope: Phenolic compounds are minor components of extra virgin olive oil (EVOO). 30 
Secoiridoids are the major components contributing to the phenolic content of EVOO. 31 
Information is lacking regarding their potential as biomarkers for EVOO intake.  32 
Methods and results: Healthy volunteers (n=9) ingested 50 mL of EVOO in a single dose 33 
containing 322 mg/kg total phenolic content (caffeic acid equivalents) and 6 mg/20g 34 
hydroxytyrosol and its derivatives. Plasma was collected before (0h) and at 0.5, 1, 2, 4 and 6h 35 
after ingestion. Urine samples were collected prior to ingestion (0h) and at 0-4, 4-8, 8-15 and 36 
15-24h. Samples were analysed by UPLC coupled with an Exactive Orbitrap MS. Partial Least 37 
Squares Discriminant Analysis with Orthogonal Signal Correction was applied to screen for 38 
metabolites that allowed samples discrimination. Plasma biomarkers and urine biomarkers were 39 
selected although individual variability was observed among volunteers. Results are in 40 
accordance with in vitro experiments performed (in vitro digestion and hepatic microsomal 41 
activity assays). 42 
Conclusions: plasma (elenolic acid + H2; p-HPEA-EA + H2 + glucuronide) and urinary (3,4-43 
DHPEA-EA, 3,4-DHPEA-EA + H2+glucuronide, methyl 3,4-DHPEA-EA + H2+glucuronide) 44 
secoiridoid compounds were selected as biomarkers to monitor EVOO intake showing good 45 
predictive ability according to multivariate analysis. 46 
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Introduction 47 
The major source of fat intake in the Mediterranean diet is olive oil (OO) and its consumption 48 
has been linked with increased longevity and a reduced frequency of chronic diseases, in 49 
particular coronary heart disease [1-5]. A European Food Safety Authority claim for OO reports 50 
that a daily consumption of 20g of OO containing at least 5 mg of hydroxytyrosol and its 51 
derivatives can protect low density lipoproteins particles from oxidative damage [6, 7]. These 52 
compounds are minor components of virgin olive oil (VOO) [8-10] and belong to the phenolic 53 
compounds family which main classes in VOO are: phenolic acids, phenolic alcohols, 54 
flavonoids, lignans and secoiridoids. The most abundant secoiridoids are the oleuropein and 55 
ligstroside aglycones - (3,4-dihydroxyphenyl)ethanol (3,4-DHPEA) and (p-56 
hydroxyphenyl)ethanol (p-HPEA) linked to elenolic acid (EA), respectively. In addition, there 57 
are also dialdehydic forms of deacetoxy of oleuropein and ligstroside aglycons (3,4-DHPEA-58 
EDA and p-HPEA-EDA, respectively) [8]. Phenolic content in VOO range from 40 to 900 59 
mg/kg expressed as caffeic acid equivalents (CAE) [8, 11]. 60 
The digestion of VOO produces a micellar solution, with reported contradictory results on the 61 
stability of the major VOO phenolics (tyrosol, hydroxytyrosol and secoiridoids 3,4-DHPEA-62 
EDA and p-HPEA-EDA) in the acidic environment of the stomach. While some identify a good 63 
stability in terms of hydrolysis [12, 13], others report that 3,4-DHPEA-EDA undergoes a rapid 64 
hydrolysis in a gastric acidic environment [14, 15] leading to an increase of hydroxytyrosol in 65 
the lumen, and consequently in plasma via passive diffusion [16, 17].  66 
The in vivo effects of VOO phenolic compounds such as hydroxytyrosol are linked to their 67 
bioavailability [18] which depends on bioaccessibility, itself a function of the food matrix. A 68 
lipid matrix, contributes to increased hydroxytyrosol bioavailability compared to an aqueous 69 
matrix or a low fat yogurt [19-21], possibly via decreased rate of gastric emptying [20] and slow 70 
release of hydroxytyrosol from the lipid matrix [20, 22].  71 
After absorption the phenolic compounds undergo phase I/II biotransformation [11, 18]. The 72 
majority of this metabolism occurs in the liver, namely in the smooth endoplasmic reticulum of 73 
the hepatocytes due to the enzymes contained in the microsomes. Phase II conjugation 74 
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processes of methylation, glucuronidation and sulfation have been described for VOO phenolic 75 
compounds [22-25].  76 
VOO phenolic compounds are mainly absorbed in the small intestine [26] via passive diffusion 77 
[16], although absorption via intestinal membrane carriers might be also involved [16, 27]. 78 
Phenolic compounds that are not absorbed in the small intestine, such as secoiridoids, are 79 
degraded by the colonic microbiota [15]. 80 
Bioavailability of VOO phenolic compounds is affected by host factors, namely age and 81 
genomic profile, enzymatic activity or colonic microflora [16, 28]. In addition, in animal studies 82 
gender appeared as a factor conditioning bioavailability of hydroxytyrosol derivatives, related 83 
with enterohepatic circulation, and longer persistence of metabolites in organisms [27]. 84 
Although secoiridoids are the most abundant and complex family of phenolic compounds in 85 
VOO, their bioavailability has been poorly studied, in part because the main products of their 86 
metabolism (via hydrolysis) are hydroxytyrosol and tyrosol. However, hydroxytyrosol is not an 87 
ideal marker of compliance of VOO intake as it is present endogenously as a metabolite of the 88 
physiological neurotransmitter dopamine and can be produced after ingestion of red wine [29]. 89 
It is therefore difficult to reduce or control hydroxytyrosol concentration in biological fluids 90 
before interventions with VOO [18]. This warrants further research into the use of secoiridoids 91 
as biomarkers for VOO intake. 92 
To obtain relevant information from metabolomics data, multivariate analysis is used [30] since, 93 
unlike univariate analysis, this approach can handle a large number of variables without 94 
requirement for the variables to be independent. Supervised methods, such as Partial Least 95 
Squares Discriminant Analysis (PLS-DA), are powerful tools in the search for markers that 96 
differ most between classes. The knowledge about the class to which a sample belongs to is 97 
used to select variables that are considerably different between groups of samples and which 98 
may be the candidate biomarkers. These approaches have been discussed in detail elsewhere 99 
[31, 32]. 100 
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The primary aim of this study was to characterize, in human subjects, the bioavailability and the 101 
inter-individual variability of secoiridoids and their metabolites after an acute extra virgin olive 102 
oil (EVOO) intake. Other typical phenolic compounds in EVOO such as phenolic acids, 103 
phenolic alcohols, flavonoids, lignans, and their metabolites, were also monitored in the 104 
samples to ascertain whether any of these could also be used to study EVOO intake. The 105 
phenolic composition of EVOO was determined by LC-MS/MS. UPLC coupled with HRMS 106 
using the Orbitrap technology was used to overcome limitations of low resolution MS 107 
techniques as several isomeric forms of the oleuropein and ligstroside aglycones have been 108 
reported [33-36]. PLS-DA was applied for data analysis to search for markers that differ most 109 
between classes (e.g.: time collection point of sample) and allow validation of class spacing 110 
numerically [37]. Digestion and hepatic microsomal in vitro models were also used to evaluate 111 
the impact of digestion and microsomal enzymatic activity on EVOO secoiridoids. To the best 112 
of our knowledge this is the first study on HRMS simultaneous screening of EVOO phenolic 113 
compounds and metabolites in plasma and urine after an acute intake of EVOO.  114 
 115 
Materials and Methods 116 
 117 
Materials 118 
Extra virgin olive oils used for human and in vitro assays were supplied by a Portuguese OO 119 
producer. Reference standards used were: apigenin, luteolin and tyrosol (≥99%), hydroxytyrosol 120 
(≥98%), and oleuropein (≥90%) purchased from Extrasynthese (Genay, France); enterolactone 121 
(≥90%), enterodiol and pinoresinol (≥95%) and caffeic acid (≥98%) purchased from Sigma-122 
Aldrich (Sigma, USA). Bile salts, DMSO, pancreatin, pepsin and sodium bicarbonate were 123 
supplied from Sigma-Aldrich (Sigma, USA). HPLC grade, ACN, methanol, water, chloridric 124 
and formic acid p.a. were purchased from Carlo Erba (Italy). HPLC grade acetic acid and 125 
sodium carbonate were supplied from Panreac (Spain). Folin–Ciocalteu reagent was supplied 126 
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from Fluka (Switzerland). Rat pooled liver microsomes and NADPH-regenerating systems were 127 
supplied from BD Gentest (Discovery Labware Inc., Woburn, MA).  128 
 129 
Human study design 130 
Nine self-reported healthy volunteers (3 males and 6 females), non-smokers and not on any 131 
medication, participated in the study and gave their written consent. Participants were aged 132 
between 24 and 61 years old (mean 34.7, SD 12.7) and had a mean BMI of 23.5 (range 20.2-133 
26.6, SD 2.4). Volunteers were required to follow a low phenolic diet (olives and any type of 134 
OO, as well as fruits, vegetables and plant products including tea and coffee were excluded) for 135 
two days and to fast overnight prior to intervention. On day 3, all fasted subjects consumed 50 136 
mL of EVOO with 30 g of white bread. This dose was selected as it ensured compliance with 137 
EFSA health claim for phenolic compounds in OO [6, 7] in line with previous bioavailability 138 
studies [38]. 139 
Venous blood samples were taken before (baseline: 0h) and 0.5, 1, 2, 4 and 6h post the 140 
ingestion. Blood was collected in heparinized tubes at each time-point and immediately 141 
centrifuged at 657 ×g for 20 min at 4ºC. Urine was collected before (baseline: 0h) and in 142 
different collection periods (0-4, 4-8, 8-15 and 15-24h) following EVOO intake. The volume of 143 
urine collected over each time period was recorded. Plasma and urine samples were frozen at -144 
80ºC prior to analysis. The study was approved by the Ethics Committee of the Faculty of 145 
Pharmacy, University of Lisbon (Permission number 02/CEECFFUL/2016). Protocols were 146 
according to the Declaration of Helsinki. 147 
 148 
Extraction of plasma 149 
Plasma samples were treated according to the method of Day et al. [39] with some 150 
modifications. ACN:formic acid (99.8:0.2, v/v) (1.25 mL) was added to 500 µL of plasma. 151 
Samples were vortexed over a 2 min period followed by 10 min ultrasound, and centrifuged at 152 
16,000 g for 10 min at 4ºC. The supernatant was collected, frozen at -80ºC, lyophilized, and 153 
suspended in 50 µL methanol:water (80:20, v/v), before analysis. The extraction procedure was 154 
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evaluated, as described in supplementary information (SI) section 1.1, by spiking pool plasma 155 
with six standard phenolic compounds (apigenin, luteolin, enterolactone, enterodiol, pinoresinol 156 
and oleuropein) at known concentrations. These standards were selected as they represent 157 
different phenolic families and cover the mass range of the majority of metabolites detected in 158 
the samples. 159 
 160 
Urine 161 
Urine samples were defrosted centrifuged at 16,000 g for 10 min at 4ºC before analysis (one 162 
freeze-thaw cycle) without further processing. 163 
 164 
Upper gastro-intestinal in vitro digestion model 165 
An EVOO was subjected to an upper gastro-intestinal in vitro digestion model (n= 6 digestions) 166 
according to Soler A. et al. [13]. Oil and aqueous phases were separated and frozen at -20ºC 167 
prior to analysis by LC-MS/MS. 168 
 169 
In vitro microsomal assays 170 
An EVOO extract (SI section 1.2) was diluted to 10-5 M (CAE equivalents) in DMSO and used 171 
as described in SI section 1.3 [40-42]. The supernatant fraction was analysed by LC-MS/MS. 172 
 173 
Total phenolic content determination 174 
The protocol described by Owen et al. [43] was used for the preparation of the phenolic 175 
compounds extract (SI section 1.2). The total phenolic content was determined [44] in triplicate 176 
(SI section 1.2).  177 
 178 
LC-MS/MS assays 179 
Details of the analysis are presented in the SI section 1.4. Hydroxytyrosol and tyrosol standards 180 
were used to quantify these compounds and their secoiridoid derivatives in EVOO (results 181 
expressed as hydroxytyrosol and tyrosol equivalents). 182 
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UPLC-Orbitrap MS assays 183 
Details of the analysis are presented in SI section 1.5. Identification was based on molecular ion 184 
and mass error tolerance (5 ppm).  185 
 186 
Data analysis 187 
The Thermo ToxID software was used to screen for EVOO phenolic compounds and 188 
corresponding metabolites in plasma and urine samples detected by UPLC-ESI-Orbitrap MS 189 
analysis. As our aim was to find discrimination patterns before and after EVOO intake, we 190 
screened for target compounds in plasma and urine samples in their free form and also as the 191 
corresponding Phase I (hydrogenation, dehydrogenation, hydration and hydroxylation) and 192 
Phase II metabolites (methylation, glucuronidation and sulfation), and mixed forms of Phase I 193 
and II metabolites (Phase I reaction + glucuronidation and/or methylation): secoiridoids and 194 
their metabolites as elenolic acid, hydroxy elenolic acid, 3,4-DHPEA-EA, 3,4-DHPEA-EDA, 195 
methyl 3,4-DHPEA-EDA, methyl 3,4-DHPEA-EA, 10-hydroxy-3,4-DHPEA-EA, 10-hydroxy-196 
3,4-DHPEA-EDA, p-HPEA-EA and p-HPEA-EDA. Other typical phenolics reported in VOO 197 
[45] were also screened: phenolic alcohols (tyrosol, hydroxytyrosol) and hydroxytyrosol 198 
acetate, phenolic acids (caffeic acid, p-coumaric acid, homovanillic acid, vanillic acid), phenolic 199 
aldehyde (vanillin), flavonoids (luteolin, apigenin) and lignans (1-acetoxypinoresinol, 200 
hydroxypinoresinol, pinoresinol, syringaresinol). All these compounds were tentatively 201 
identified by their exact mass. Criteria for variable inclusion in multivariate analysis were 202 
absence at 0h time point in plasma and urine [23] and presence in samples from at least two 203 
volunteers post EVOO ingestion. Participants were instructed to follow a low phenolic diet 204 
that excluded olives and any type of OO. Therefore by excluding variables present at baseline 205 
the variations in possible markers would be related to EVOO consumption minimizing 206 
interference due to other dietary components.  207 
Alignment of retention time and m/z values was carried out across samples using a tolerance 208 
window of 5 ppm. Normalization of peak area of selected variables was performed using peak 209 
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area/total peak area for each chromatogram, and expressed as ppm (Peak area/total peak area X 210 
1,000,000). Normalization allowed removal of systemic variation between spectra due to 211 
variations in sample or equipment. Partial Least Squares Discriminant Analysis with Orthogonal 212 
Signal correction (OSC-PLS-DA) was performed using SIMCA-P+ 13.0 software (SI section 213 
1.6).  214 
Determination of excretion of urinary biomarkers was done using hydroxytyrosol as standard. 215 
Normalized peak areas of the selected variables in urine were used for quantification. Values 216 
were corrected according to volume of urine collected per sample point. 217 
 218 
Results  219 
Phenolic composition of EVOO 220 
The EVOO ingested had a total phenolic content of 322 ± 6 mg/kg CAE and 6 mg/20g 221 
hydroxytyrosol and its derivatives and therefore meeting the EFSA recommendation for 222 
phenolic compounds in olive oil [6, 7]. Each volunteer ingested 14.7 mg of phenolics.  223 
Individual characterization of phenolic compounds in this EVOO is presented in Table 1. 224 
 225 
In vitro upper gastro-intestinal digestion and microsomal assays  226 
The in vitro digestion process led to a secoiridoids decrease (–0.49 fold change) due to chemical 227 
hydrolysis and an increase in phenolic alcohols (hydroxytyrosol: 1.66 fold change and 228 
tyrosol:0.64 fold change) in medium (SI section 2.1 Table S1). Secoiridoids were still detected 229 
in the oil phase, after digestion, showing that they were still available for absorption and 230 
metabolism. In vitro microsomal assays enabled to conclude that 3,4-DHPEA-EA and p-HPEA-231 
EA decayed in the assay medium along with increases in the corresponding hydrogenated 232 
metabolites (SI section 2.2 Figure S1). Calculated half-life in rat liver microsomes was 14.4 h 233 
for 3,4-DHPEA-EA and 7.2 h for p-HPEA-EA. 234 
 235 
OSC-PLS-DA applied to plasma and urine results 236 
Plasma samples  237 
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Validation tests were performed for plasma extraction and results are presented in SI section 2.3 238 
(Tables S2 and S3). Eighteen compounds in plasma samples were selected as variables 239 
according to inclusion criteria (Table 2) and used for multivariate analysis. Possible isomeric 240 
forms were detected for several secoiridoid compounds, as reported before [36]. 241 
The parameters used to assess the OSC-PLS-DA modelling quality are summarized in Table 3. 242 
With the exception of the model with all plasma samples evaluated at the same time (data not 243 
shown), all OSC-PLS-DA models presented acceptable values for all quality and validation 244 
parameters, indicative that they were able to discriminate samples from baseline. These OSC-245 
PLS-DA models (baseline vs. each time collection point) explained between 27.9 and 41.2% of 246 
the metabolite intensity variation (R2X) and between 75.3 and 97.3% of the time point variation 247 
(R2Y). In our work prediction values Q2 were between 62.1 and 93.6% after cross-validation, 248 
indicating good predictive ability of the models. 249 
Permutation tests allowed assessment of overfitting. Models were considered valid as the 250 
average of the R2 values of the permuted models were less than half the R2 value of the original 251 
model, indicating that more than half of the explained variability was not due to change [46]. 252 
p(corr) values were calculated for each of the models and are presented SI section 2.4 (Table 253 
S4). Three variables (P1A, P1B and P9B) were discriminant for all time points and were 254 
selected as plasma biomarkers to monitor EVOO intake. Two other variables were 255 
discriminatory for one time point (SI section 2.4 Table S4) and nine variables were 256 
discriminant for two to four time points (SI section 2.4 Table S4). 257 
 258 
Urine samples 259 
Following the same approach, thirty-two compounds were selected in urine as variables for PLS 260 
analysis (Table 4). With the exception of the model with all samples evaluated at the same time 261 
(data not shown), all OSC-PLS-DA models presented acceptable values for all quality and 262 
validation parameters, indicative that they were able to discriminate samples when compared 263 
with baseline samples (Table 5). These OSC-PLS-DA models (baseline vs. each time collection 264 
point) explained between 48.0 and 61.0% of the metabolite intensity variation (R2X) and 265 
Page 10 of 31Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 11 
 
between 80.0 and 100% of the time point variation (R2Y), with prediction values Q2 between 266 
77.6 and 99.4% after cross-validation. The obtained values of permutation tests were considered 267 
acceptable. p(corr) values were calculated for each of the models and are presented in SI section 268 
2.4 (Table S5). Nine variables were discriminant for all time points when compared with 269 
baseline samples (U2, U9D, U9F, U9G, U9H, U11A, U11B, U11D and U11E). These variables 270 
were selected as urinary biomarkers to monitor EVOO intake. Other four variables were 271 
discriminant for one time point (SI section 2.4 Table S5) and eighteen variables where 272 
discriminant for two or three time points (SI section 2.4 Table S5).  273 
 274 
Absorption and excretion profile of selected plasma and urinary biomarkers 275 
Absorption profiles of the discriminant plasma biomarkers presented maximum levels between 276 
0.5 and 2h after EVOO intake, depending on each volunteer (Figure 1). In Figure 2 are shown 277 
the excretion profiles of the nine discriminant urinary biomarkers, all hydroxytyrosol 278 
derivatives. Maximum concentrations in human urine were reached in the time period of 0-4h 279 
after oil intake and mean values for the nine volunteers are presented. The total amount excreted 280 
(24h) of each selected biomarker per volunteer is presented in Figure 3. 281 
 282 
Discussion 283 
Within this work HRMS was used as a tool to identify, with a high selectivity and low error, the 284 
detected metabolites in plasma and urine samples after EVOO intake. ESI negative ionization 285 
mode was selected as it is more sensitive than the positive ionization mode [23, 47]. Moreover 286 
this approach overcomes complex sample preparation procedures related with GC-MS analysis 287 
[48].  288 
Data obtained from UPLC-HRMS analysis of samples were treated by PLS-DA in order to 289 
maximize the separation of observations (plasma and urine samples) belonging to the different 290 
classes that have previously been defined (different time points in the study). This procedure 291 
allowed to establish a model to predict the class (variable Y) from the compounds measured in 292 
the UPLC-HRMS analysis (X variables). Orthogonal signal correction (OSC), a multivariate 293 
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pre-processing data filter, was used before proceeding with the PLS-DA to eliminate the signal 294 
information (X) that is unrelated (orthogonal) to the classes (Y) [49, 50]. Using this approach it 295 
was possible, to select biomarkers that were the best predictors of the class vector. 296 
The OSC-PLS-DA models with all samples evaluated at the same time did not meet quality 297 
criteria. This could be due to the low number of variables and/or due to criteria used for 298 
variables inclusion (absence at baseline). Therefore, further models were performed at each time 299 
point to analyse the separation of samples of each time point compared with baseline samples. 300 
Using this approach three plasma secoiridoid compounds (elenolic acid + H2 detected at two 301 
retention times; p-HPEA-EA + H2 + glucuronide) and nine urinary (3,4-DHPEA-EA, 3,4-302 
DHPEA-EA + H2+glucuronide detected at four retention times, and methyl 3,4-DHPEA-EA + 303 
H2 + glucuronide detected at four retention times) secoiridoid compounds were selected as 304 
biomarkers for monitoring EVOO intake in human intervention trials, as they were discriminant 305 
for all time collection points when compared to baseline. Moreover other secoiridoids were 306 
identified in plasma and urine as enabling discrimination of one or more time points. It is worth 307 
noting that although other phenolic compounds and metabolites were monitored in plasma and 308 
urine samples, the secoiridoids group clearly stood apart in terms of sample discrimination, 309 
results in agreement with others [23]. 310 
In our study the results from the in vitro experiments with microssomes showed that 311 
secoiridoids 3,4-DHPEA-EA and p-HPEA-EA were stable, when incubated with liver 312 
microsomes, with half-lives longer than 6h. A search for metabolites, allowed us to detect 313 
compounds, identified as the hydrogenated forms of the parent compounds. Although there are 314 
differences between rat and human microsomal activity, hydrogenation seems to be an 315 
important Phase I route of metabolism for these secoiridoids. This evidence was supported by 316 
results obtained in the human intervention as hydrogenated metabolites were detected in plasma 317 
for elenolic acid, a structural unit of phenolic secoiridoids. Therefore, the detection of elenolic 318 
acid in plasma (hydrogenated form) could be related with hydrolysis of oleuropein and 319 
ligstroside aglycones in the gastric or intestinal environment, as evidenced after in vitro 320 
digestion of EVOO. Discriminating metabolites resulting from Phase I metabolism, concerning 321 
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hydroxylation and hydration, were also detected in plasma such as p-HPEA-EDA + H2O and 322 
3,4-DHPEA-EA + OH. These compounds discriminated samples for two to four time collection 323 
points. Our results are in accordance with others [23], that identified these metabolites as 324 
enabling discrimination in human urines before and after EVOO intake.  325 
Absorption and metabolism of the secoiridoids 3,4-DHPEA-EDA and 3,4-DHPEA-EA was 326 
studied before [12], by using perfused segments of jejunum and ileum, and hydrogenation 327 
followed by glucuronidation of these compounds was reported. Authors attributed the reduced 328 
metabolite forms to the action of NADPH-dependent aldo-keto reductases present in the small 329 
intestine. In our study, hydrogenated forms of p-HPEA-EDA and p-HPEA-EA glucuronides 330 
were also detected in plasma. Moreover, p-HPEA-EA + H2 + glucuronide was selected within 331 
this work as a discriminating plasma metabolite.  332 
In urine, 3,4-DHPEA-EA + H2 + glucuronide and methyl 3,4-DHPEA-EA + H2 + glucuronide 333 
were selected as biomarkers of EVOO intake for all time collection points. The higher polarity 334 
of 3,4-DHPEA-EA and methyl 3,4-DHPEA-EA hydrogenated glucuronides compared with p-335 
HPEA-EDA and p-HPEA-EA corresponding metabolites, might explain their presence in urine 336 
and not in plasma. As the action site of NADPH-dependent aldo-keto reductases is in the 337 
elenolic acid unit [12] the same reactions can take place in oleuropein or ligstroside aglycones. 338 
Moreover hydrogenated metabolites of p-HPEA-EA and 3,4-DHPEA-EA glucuronides were 339 
selected before as human urinary biomarkers for EVOO intake [23].  340 
It is worth noting the selection of 3,4-DHPEA-EA as discrimination marker in urine. This 341 
typical EVOO phenolic compound was also selected as marker in plasma, however not for all of 342 
the collection points. Other urinary discrimination markers included 3,4-DHPEA-EA + H2 + 343 
glucuronide and methyl-3,4-DHPEA-EA + H2 + glucuronide. The presence of methylated forms 344 
might be explained by the action of catechol-O-methyl-tranferase that catalyzes the transfer of a 345 
methyl group from S-adenosyl-L-methionine to phenolic compounds having an o-diphenolic 346 
structure [51], although methyl 3,4-DHPEA-EA was also present in the EVOO.  347 
In our study, glucuronide metabolites of p-HPEA-EDA, 3,4-DHPEA-EDA and methyl 3,4-348 
DHPEA-EDA, were detected as major metabolites in urine, as were glucuronides of methyl 3,4-349 
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DHPEA-EDA + OH, methyl 3,4-DHPEA-EA + H2 and 3,4-DHPEA-EA + H2/OH/H2O. 350 
Glucuronides of p-HPEA-EDA, 3,4-DHPEA-EA + H2/OH/ H2O, and methyl 3,4-DHPEA-EDA 351 
+ OH were previously identified in human urine samples after intake of EVOO [23]. 352 
Glucuronides of secoiridoids 3,4-DHPEA-EDA and 3,4-DHPEA-EA derivatives were detected 353 
in human plasma samples after a bioavailability study with VOO [16]. In our study glucuronides 354 
of hydrogenated forms of p-HPEA-EDA and p-HPEA-EA were also detected in plasma as well 355 
as glucuronide of methyl 3,4-DHPEA-EDA+H2O. UDP-glucuronosyltransferases are 356 
membrane-bounded enzymes that are located in the endoplasmic reticulum in many tissues and 357 
catalyze the transfer of a glucuronic acid from UDP-glucuronic acid to phenolic compounds or 358 
xenobiotics [51].  359 
Metabolites of the secoiridoid group were detected with the same exact mass but at different 360 
retention times, suggesting the presence of isomers, which could be justified by the ring opening 361 
in the secoiridoid structure, due to keto-enolic tautomeric equilibrium [52]. The presence of two 362 
putative groups of isomers for secoiridoid derivatives as elenolic acid, oleuropein and 363 
ligstroside aglycones was previously reported [36]. 364 
Maximum absorption levels of the plasma biomarkers were detected between 0.5 and 2h and 365 
results are in accordance with others (maximum at 1h) [16]. Maximum excretion of urinary 366 
biomarkers occurred in the first 4h after EVOO intake and results are in accordance with others 367 
(maximum between 2 - 4h) [23]. Variability of results among volunteers was high for the 368 
selected biomarkers in plasma and urine which is reflected in the standard deviations obtained. 369 
Bioavailability of phenolic compounds not only depends on their concentration in the VOO but 370 
is also affected by the individual genomic profile with impact on enzymatic activity involved in 371 
the digestion and metabolism process. In fact polymorphism expression of conjugation enzymes 372 
[51] or individual variations in digestive enzymes [53] or bile salts [54] might justify the 373 
variations observed.  374 
VOO phenolics undergo rapid absorption and fast renal elimination as evidenced in the 375 
absorption and excretion profiles of the selected biomarkers. Accumulation of metabolites in 376 
target tissues, studied before [55], could be considered when investigating the potential 377 
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bioactivity of VOO phenolic compounds. In this work, the lack of pure standards did not allow 378 
the calculation of a mass balance between the ingested EVOO phenolics, plasma and urinary 379 
metabolites and pharmacokinetic data. 380 
The use of secoiridoids as biomarkers to monitor EVOO intake has the advantage of specificity. 381 
While phenolic acids, phenolic alcohols and flavonoids occur in many fruits and vegetables 382 
belonging to various botanical families, secoiridoids are present exclusively in plants belonging 383 
to the family of Oleaceae including the olive tree Olea europaea L. [8]. Results of this work 384 
highlight the importance of secoiridoids as biomarkers of EVOO intake. These biomarkers 385 
would allow monitoring compliance of following the dose in interventions aimed to evaluate 386 
health benefits of EVOO intake in accordance with the EFSA claim [5]. Although secoiridoids 387 
are the major components in the phenolic fraction of EVOO [56], we have to take into account 388 
that several factors influence its content in EVOO. Olive tree cultivars, alternate bearing of the 389 
olive tree, environmental conditions, maturity of the fruits or technological factors are 390 
parameters that influence chemical composition of EVOO and therefore increase variability in 391 
the phenolic composition [1, 8, 57, 58]. The combination of digestion models with in vitro 392 
approaches of hepatic metabolism (e.g.: incubation with HepG2 cells or liver microsomes) can 393 
be useful in producing metabolites from EVOO. Recently it was demonstrated the use of Caco-2 394 
cells as bioreactors for generation of phase II metabolites of hydroxytyrosol [59]. This approach 395 
would allow us to confirm the identity of biomarkers selected in this work. After identification 396 
it would be possible to produce biomarkers as authentic standard allowing absolute calibration 397 
of these compounds in samples. Moreover the use of HRMS/MS would enable structural 398 
clarification of the putatively identified isomers.  399 
The secoiridoid metabolites detected in plasma and urine samples from volunteers were able to 400 
discriminate between different time points after EVOO intake. The most common metabolic 401 
reactions were Phase I hydrogenation and Phase II glucuronidation. The selected secoiridoid 402 
biomarkers can be added to the ones already described. Due to the variability in absorption, 403 
metabolism and elimination of compounds, future studies should include broader populations to 404 
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account for inter-individual variability. The role of the identified metabolites in beneficial health 405 
effects requires further investigation. 406 
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Figure 1 - Plasma absorption-time profiles of variables P1A (elenolic acid + H2), P1B (elenolic 627 
acid + H2 detected at a different retention time) and P9B (p-HPEA-EA+H2+glucuronide) for 628 
volunteers (1 to 9) and mean values. Data are expressed as normalized areas (ppm) 629 
 630 
Figure 2 - Excretion profile of discriminatory biomarkers identified in urine after EVOO intake 631 
(µg excreted expressed as hydroxytyrosol equivalents). Data are expressed as mean ± SD 632 
 633 
Figure 3 – Total excretion of discriminatory biomarkers identified in urine (0-24h) per volunteer 634 
(n=9) after EVOO intake (µg of hydroxytyrosol equivalents) 635 
 636 
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 654 
 655 
Table 1 – Phenolic compounds and elenolic acid in EVOO used in the human intervention 656 
identified by LC-MS/MS 657 
Retention 
time 
(min) 
[M-H]- 
m/z 
Ion 
Formula 
MS/MS 
m/z 
Compound EVOO 
(mg/kg) 
    
3.6 153 C8H9O3 123, 95 Hydroxytyrosol 3.75 
5.3 137 C8H9O2 119, 106 Tyrosol 2.09 
19.3 377 C19H21O8 275, 307 3,4-DHPEA-EA* 51.49 
16.7 319 C17H19O6 195, 183 3,4-DHPEA-EDA* 9.78 
18.3 391 C20H23O8 377 Methyl 3,4-DHPEA-
EA* 
4.15 
15.6 335 C17H19O7 199, 155 OH - deacetoxy 
oleuropein aglycone* 
1.12 
17.4 393 C19H21O9 317 10-OH oleuropein 
aglycone* 
5.67 
21.0 361 C19H21O7 291, 259 p-HPEA-EA** 203.08 
18.5 303 C17H19O5 285, 179 p-HPEA-EDA** 30.08 
14.3 241 C11H13O6 139 Elenolic acid* 10.04 
17.4 285 C15H9O6 133 Luteolin 3.19 
18.7 269 C15H9O5 151 Apigenin 0.70 
17.6 357 C20H21O6 151, 136 Pinoresinol* 0.49 
17.6 415 C22H23O8 235, 151 Acetoxipinoresinol* 0.24 
11.2 151 C8H7O3 136 Vanillin 0.14 
*Quantified as hydroxytyrosol equivalents; **quantified as tyrosol equivalents. 658 
 659 
 660 
 661 
 662 
 663 
 664 
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Table 2 - Retention time, theoretical and experimental m/z, error and ion formula obtained in 665 
negative mode for compounds detected in plasma (P) and considered as variables for OSC-PLS-666 
DA and corresponding abbreviations  667 
Variables included 
 in OSC-PLS-DA 
Retention 
time (min) 
Theoretical m/z Experimental 
m/z
a 
Error 
(ppm)a 
Ion Formula Abbreviationb 
Elenolic acid + H2 10.35 243.0874 243.0862 -4.9 C11H15O6 P1A 
Elenolic acid + H2 10.97 243.0874 243.0863 -4.5 C11H15O6 P1B 
3,4-DHPEA-EDA 13.34 319.1187 319.1174 -4.2 C17H19O6 P2 
p-HPEA-EDA + H2O  13.01 321.1344 321.1333 -3.2 C17H21O6 P3 
3,4-DHPEA-EA 9.70 377.1242 377.1250 2.2 C19H21O8 P4 
3,4-DHPEA-EA+OH 13.68 393.1191 393.1175 -4.0 C19H21O9 P5A 
3,4-DHPEA-EA+OH 13.94 393.1191 393.1173 -4.5 C19H21O9 P5B 
p-HPEA-EDA + H2 + glucuronide 9.97 481.1715 481.1700 -3.2 C23H29O11 P6A 
p-HPEA-EDA + H2 + glucuronide 10.24 481.1715 481.1701 -2.9 C23H29O11 P6B 
p-HPEA-EDA + H2 + glucuronide 10.56 481.1715 481.1701 -2.9 C23H29O11 P6C 
3,4-DHPEA-EDA+OH+glucuronide 11.14 511.1457 511.1480 4.4 C23H27O13 P7 
Methyl 3,4-DHPEA-EDA + H2O + glucuronide  10.12 527.1770 527.1753 -3.3 C24H31O13 P8A 
Methyl 3,4-DHPEA-EDA + H2O + glucuronide 10.35 527.1770 527.1756 -2.7 C24H31O13 P8B 
Methyl 3,4-DHPEA-EDA + H2O + glucuronide 10.71 527.1770 527.1755 -2.9 C24H31O13 P8C 
p-HPEA-EA + H2 +glucuronide 11.73 539.1770 539.1757 -2.4 C25H31O13 P9A 
p-HPEA-EA + H2 + glucuronide 11.94 539.1770 539.1758 -2.3 C25H31O13 P9B 
p-HPEA-EA + H2 + glucuronide 12.15 539.1770 539.1759 -2.1 C25H31O13 P9C 
Apigenin+CH3+glucuronide 11.33 459.0933 459.0949 3.5 C22H19O11 P10 
a mean value. 668 
b letters account for putative isomers. 669 
Compounds highlighted in bold enabled plasma samples discrimination after EVOO intake, for 670 
all collection points, as found by OSC-PLS-DA 671 
 672 
 673 
 674 
 675 
 676 
 677 
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Table 3 – Summary of parameters for assessing the OSC-PLS-DA modeling quality in plasma 678 
samples 679 
Model 
OSC Filter OSC-PLS-DA 
Permutation 
test 
N Â 
remaining 
SS (%) 
eigen-
value 
N 
R2X 
(cum) 
R2Y 
(cum) 
Q2 
(cum) 
p-value R2 Q2 
 t0h vs. t0,5h 1 90.00 79.76 3.441 1 0.315 0.973 0.936 1.07x10-9 0.117 -0.251 
 t0h vs. t1h 1 90.00 72.12 4.739 1 0.412 0.911 0.850 6.72x10-7 0.074 -0.239 
 t0h vs. t2h 1 90.00 72.00 4.760 1 0.389 0.879 0.801 5.56x10-6 0.123 -0.224 
 t0h vs. t4h 1 90.00 67.04 4.943 1 0.364 0.866 0.779 1.22x10-5 0.140 -0.203 
 t0h vs. t6h 1 90.00 71.70 3.962 1 0.279 0.753 0.621 6.90x10-4 0.131 -0.157 
N, number of components in OSC and PLS-DA model, respectively; Â displays the angle 680 
between the component and the Y variable; SS, sum of squares, indicating the % of the original 681 
variance in the X-block that remains in the corrected X-matrix; R2X(cum) and R2Y(cum) are the 682 
cumulative modelled variation in the X and Y matrix, respectively; Q2(cum) is the cumulative 683 
predicted variation in the Y matrix; the p-value from CV-ANOVA, based on the cross-validated 684 
predictive residuals, is listed for both models (significant result indicates a valid model). 685 
 686 
 687 
 688 
 689 
 690 
 691 
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Table 4 - Retention time, theoretical and experimental m/z, error and ion formula obtained in 692 
negative mode for compounds detected in urine (U) and considered as variables for OSC-PLS-693 
DA and corresponding abbreviations 694 
Variables included 
 in OSC-PLS-DA 
Retention 
time (min) 
Theoretical 
m/z 
Experimental 
m/z
a 
Error 
(ppm)a 
Ion Formula Abbreviationb 
p-HPEA-EA +H2 23.06 363.1449 363.1443 -1.7 C19H23O7 U1 
3,4-DHPEA-EA  22.86 377.1242 377.1233 -2.2 C19H21O8 U2 
3,4- DHPEA-EA + OH +Sulfate 16.40 473.0759 473.754 -1.2 C19H21O12S U3A 
3,4-DHPEA-EA + OH +Sulfate 16.89 473.0759  473.0751 -1.7 C19H21O12S U3B 
Luteolin + CH3+glucuronide 12.80 475.0882  475.0905 4.8 C22H19O12 U4  
p-HPEA-EDA +glucuronide 15.48 479.1559 479.1548 -2.2 C23H27O11 U5A 
p-HPEA-EDA +glucuronide 16.39 479.1559  479.1549 -2.1 C23H27O11 U5B 
3,4-DHPEA-EDA+glucuronide  15.18 495.1508  495.1498 -2.0 C23H27O12 U6  
Methyl 3,4-DHPEA-EDA +glucuronide 16.88 509.1665  509.1653 -2.2 C24H29O12 U7A 
Methyl 3,4-DHPEA-EDA +glucuronide 18.08 509.1665  509.1653 -2.3 C24H29O12 U7B 
Methyl 3,4-DHPEA-EDA + OH+glucuronide 13.09 525.1614  525.1619 2.9 C24H29O13 U8A 
Methyl 3,4-DHPEA-EDA + OH+glucuronide 13.15 525.1614  525.1623 1.8 C24H29O13 U8B 
Methyl 3,4-DHPEA-EDA + OH+glucuronide 16.17 525.1614  525.1608 -1.0 C24H29O13 U8C 
Methyl 3,4 DHPEA-EDA + OH+glucuronide 16.50 525.1614  525.1607 -1.3 C24H29O13 U8D 
3,4-DHPEA-EA + H2+glucuronide 13.49 555.1719  555.1707 -2.3 C25H31O14 U9A 
3,4-DHPEA-EA + H2+glucuronide 13.71 555.1719  555.1706 -2.3 C25H31O14 U9B 
3,4-DHPEA-EA + H2+glucuronide 13.82 555.1719  555.1706 -2.3 C25H31O14 U9C 
3,4-DHPEA-EA + H2+glucuronide 16.50 555.1719  555.1707 -2.3 C25H31O14 U9D 
3,4-DHPEA-EA + H2+glucuronide 16.61 555.1719 555.1706 -2.3 C25H31O14 U9E 
3,4-DHPEA-EA + H2+glucuronide 16.87 555.1719 555.1706 -2.3 C25H31O14 U9F 
3,4-DHPEA-EA + H2+glucuronide 17.76 555.1719 555.1706 -2.4 C25H31O14 U9G 
3,4-DHPEA-EA + H2+glucuronide 18.09 555.1719 555.1706 -2.3 C25H31O14 U9H 
3,4-DHPEA-EA + OH+glucuronide 14.33 569.1512 569.1533 3.7 C25H29O15 U10A 
3,4-DHPEA-EA + OH+glucuronide 14.68 569.1512 569.1518 1.0 C25H29O15 U10B 
3,4-DHPEA-EA + OH+glucuronide 14.80 569.1512 569.1539 4.8 C25H29O15 U10C 
Methyl 3,4-DHPEA-EA + H2+glucuronide 17.69 569.1876 569.1865 -1.9 C26H33O14 U11A 
Methyl 3,4-DHPEA-EA + H2+-glucuronide 17.89 569.1876 569.1865 -1.9 C26H33O14 U11B 
Methyl 3,4-DHPEA-EA + H2+glucuronide 17.97 569.1876 569.1864 -2.0 C26H33O14 U11C 
Methyl 3,4-DHPEA-EA + H2+glucuronide 19.33 569.1876 569.1865 -1.9 C26H33O14 U11D 
Methyl 3,4-DHPEA-EA + H2+glucuronide 19.66 569.1876 569.1868 -1.4 C26H33O14 U11E 
3,4-DHPEA-EA + H2O+glucuronide 12.99 571.1668 571.1660 -1.5 C25H31O15 U12A 
3,4-DHPEA-EA + H2O+glucuronide 13.52 571.1668 571.1658 -1.9 C25H31O15 U12B 
a mean value. 695 
b letters account for putative isomers. 696 
Compounds highlighted in bold enabled urine samples discrimination after EVOO intake, for all 697 
collection points, as found by OSC-PLS-DA. 698 
 699 
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Table 5 – Summary of parameters for assessing the OSC-PLS-DA modeling quality in urine 700 
samples 701 
Model 
OSC Filter OSC-PLS-DA Permutation test 
N Â 
remaining 
SS (%) 
eigen-
value 
N 
R2X 
(cum) 
R2Y 
(cum) 
Q2 
(cum) 
p-value R2 Q2 
 t0h vs. t0-4h 1 89.99 80.35 3.538 1 0.573 0.800 0.776 1.36x10-05 0.096 -0.216 
 t0h vs. t4-8h 1 90.00 75.18 4.219 1 0.610 1.000 0.994 3.02x10-16 0.032 -0.260 
 t0h vs. t8-15h 1 90.00 68.95 5.589 1 0.480 0.998 0.988 5.07x10-15 0.029 -0.277 
 t0h vs. t15-24h 1 90.00 68.40 4.740 1 0.560 0.997 0.986 8.84x10-14 0.008 -0.266 
N, number of components in OSC and PLS-DA model, respectively; Â displays the angle 702 
between the component and the Y variable; SS, sum of squares, indicating the % of the original 703 
variance in the X-block that remains in the corrected X-matrix; R2X(cum) and R2Y(cum) are the 704 
cumulative modelled variation in the X and Y matrix, respectively; Q2(cum) is the cumulative 705 
predicted variation in the Y matrix; the p-value from CV-ANOVA, based on the cross-validated 706 
predictive residuals, is listed for both models (significant result indicates a valid model). 707 
 708 
 709 
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Plasma absorption-time profiles of variables P1A (elenolic acid + H2), P1B (elenolic acid + H2 detected at a 
different retention time) and P9B (p-HPEA-EA+H2+glucuronide) for volunteers (1 to 9) and mean values. 
Data are expressed as normalized areas (ppm)  
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Excretion profile of discriminatory biomarkers identified in urine after EVOO intake (µg excreted expressed 
as hydroxytyrosol equivalents). Data are expressed as mean ± SD  
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Total excretion of discriminatory biomarkers identified in urine (0-24h) per volunteer (n=9) after EVOO 
intake (µg of hydroxytyrosol equivalents)  
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 Secoiridoids are the major components contributing to the phenolic content of extra 
virgin olive oil (EVOO). Healthy volunteers (n=9) ingested 50 mL of EVOO in a single 
dose containing 6 mg/20 g of hydroxytyrosol and its derivatives. High resolution mass 
spectrometry and multivariate analysis enabled the identification of plasma and urinary 
secoiridoid compounds as biomarkers of EVOO intake. 
Page 31 of 31 Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
